A Phase 2/3 interventional study of Cohort 1 CTAP101 Capsules- 60µg and Cohort 1 CTAP101 Capsules - 90µg in Chronic Kidney Disease, Secondary Hyperparathyroidism and Vitamin D Insufficiency, sponsored by OPKO Health, Inc.. Completed at 1 site in United States. Open to participants aged 18 Years to 85 Years. Per ClinicalTrials.gov, last updated 2016-08-25.
Sponsored by OPKO Health, Inc. · Phase 2/3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 988 studies in Renal Insufficiency, Chronic with a site in United States — 170 open to participants now, 218 under way, 25 of them phase 3. Renal Insufficiency, Chronic · United States.
Among the 988 studies in Renal Insufficiency, Chronic with a site in United States, this one is the 399th largest by enrollment of the 819 interventional ones that give a count, is one of 42 that started in 2010, is one of 13 in phase 2/3, and was the 185th registered.
3,096 studies on the registry are indexed under Renal Insufficiency, Chronic; 701 are open to participants now.
Browse Renal Insufficiency, Chronic studies →170 of the 988 studies in Renal Insufficiency, Chronic with a site in United States are open now. Recruiting first, the newest first:
University of Chicago · Sites in United States
Ages 18–70
Indiana University · Sites in United States
Ages 40–70
Bettina Mittendorfer · Sites in United States
Ages 18–100 · Healthy volunteers
University of Minnesota · Sites in United States
Ages 30–75
United Therapeutics · Sites in United States
Ages 40–70
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 434 Renal Insufficiency, Chronic studies recruiting now, 244 (56%) set no upper age limit and 110 (25%) stop at 75 or younger; 44 take children under 18; 80 take healthy volunteers.
This study: 18 Years to 85 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
988 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 109 · Phase 2 185 · Phase 3 160 · Phase 4 81
First in 1988; this study’s year is marked. 42 started in 2010.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 78 is close to the median of 73 across 2,162 interventional studies indexed under Renal Insufficiency, Chronic.
Median enrollment 72 across the 819 interventional studies, 125 across the 165 observational. Of the 696 that completed or were terminated, 344 (49%) have results posted.
This tab as a report to print or save as PDF → With an account.
372 of 988 have an industry lead sponsor. The 10 most frequent:
OPKO Health, Inc. is the lead sponsor of 49 studies on the registry; 2 are open to participants now.
Of its 9 completed or terminated interventional studies of FDA-regulated products, 7 (78%) have results posted.
OPKO Health, Inc. has 9 studies filed under Renal Insufficiency, Chronic — fewer than ten, so there is no comparison to draw.
73 of the studies in Renal Insufficiency, Chronic with a site in United States that are under way reach primary completion within a year, 5 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT03565913Phase 3University of Texas Southwestern Medical CenterPotential Therapeutic Role of Effervescent Calcium-Magnesium Citrate in Chronic Kidney Disease Stage V | 2026-12-01 |
| NCT06531824Phase 3Boehringer IngelheimEASi-KIDNEY™ (The Studies of Heart & Kidney Protection With BI 690517 in Combination With Empagliflozin) | 2026-12-31 |
| NCT05196035Phase 3BayerA Study to Learn More About How Well the Study Treatment Finerenone Works, How Safe it is, How it Moves Into, Through, and Out of the Body, and the Effects it Has on the Body When Taken With an ACE Inhibitor or Angiotensin Receptor Blocker in Children With Chronic Kidney Disease and Proteinuria | 2027-04-10 |
| NCT07107945Phase 3Boehringer IngelheimA Study to Find Out How EMPAgliflozin is Tolerated and if it Helps Children and Adolescents With Chronic KIDNEY Disease (EMPA-KIDNEY® Kids) | 2027-04-16 |
| NCT05852938Phase 3Novartis PharmaceuticalsA Study of Zigakibart in Adults With IgA Nephropathy | 2027-08-10 |
Add all 73 to your calendar (.ics) → With an account.
Among the 988 studies in Renal Insufficiency, Chronic with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This study will investigate how the levels of a repeat dose of CTAP101 changes in the body over time (pharmacokinetics, PK) and how CTAP101 affects other mineral and hormonal balances (pharmacodynamics, PD) in patients with chronic kidney disease (CKD, vitamin D insufficiency and secondary hyperparathyroidism (SHPT).
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: Cohort 1 CTAP101 Capsules- 60µg
Drug: Cohort 1 CTAP101 Capsules - 90µg
Drug: Cohort 1 Matching Sugar Capsule
Drug: Cohort 2 CTAP101 Capsules - 30µg
Drug: Cohort 2 Matching Sugar Capsule
60µg of CTAP101 capsules given once daily for 42 days.
90µg of CTAP101 capsules given once daily for 42 days.
Placebo capsules given once daily for 42 days.
30µg of CTAP101 capsules given once daily for 42 days.
Placebo capsules given once daily for 42 days.
Proportion (%) of Subjects With Serum 25-hydroxyvitamin D ≥30 ng/mL (PP).
The proportion of subjects in the per protocol population with serum 25-hydroxyvitamin D ≥30 ng/mL at End-of-Treatment (EOT; Week 6) in Cohorts 1 and 2 (60/90 and 30 μg groups, respectively) were compared to their corresponding placebo groups.
Time frame: 6 weeks
Mean Percent Change From Baseline in Plasma Intact Parathyroid Hormone (iPTH) to End of Treatment (Per Protocol Population)
Mean percent change from baseline in plasma intact parathyroid hormone (iPTH) from baseline to End of Treatment (EOT) in the Per Protocol population. Subjects in Cohorts 1 and 2 (dose regimens 60/90 and 30 mcg, respectively) were compared to their respective placebo groups.
Time frame: 6 weeks
Change From Baseline in Serum 25-hydroxyvitamin D at Week 6
Mean absolute change from baseline in serum total 25-hydroxyvitamin D to end of treatment (EOT)
Time frame: Baseline to End of Treatment (6 weeks)
Percent Change From Baseline in Serum 25-hydroxyvitamin D at End of Treatment (EOT, Week 6) in the Per Protocol Population
Mean percent change from baseline in serum 25-hydroxyvitamin D at End of Treatment (EOT, week 6) in the per protocol population. Subjects in Cohorts 1 and 2 (dose regimens of 60/90 and 30 mcg, respectively) were compared versus their corresponding placebo groups.
Time frame: Baseline to End of Treatment (6 weeks)
Proportion of Subjects With Reduction of Intact Parathyroid Hormone (iPTH) of at Least 30% at Week 6
Proportion of subjects with at least 30% reduction in plasma intact parathyroid hormone (iPTH) and/or mean iPTH reduction to 70 pg/mL or less at End of Treatment (EOT)
Time frame: Baseline to End of Treatment (6 weeks)
Proportion of Subjects With Reduction of Intact Parathyroid Hormone (iPTH) of at Least 20% at Week 6
Proportion of subjects with at least 20% reduction in plasma intact parathyroid hormone (iPTH) and/or mean iPTH reduction to 70 pg/mL or less at End of Treatment (EOT)
Time frame: Baseline to End of Treatment (6 weeks)
Subjects with Stage 3 chronic kidney disease, vitamin D insufficiency and secondary parahyperthyroidism were recruited from 16 sites within the US.
| Milestone | Cohort 1: CTAP101 Capsules 60µg | Cohort 1: CTAP101 Capsules 90µg | Cohort 1: Sugar Capsule | Cohort 2: CTAP101 Capsules 30µg | Cohort 2: Sugar Capsule |
|---|---|---|---|---|---|
| Started | 17 | 17 | 17 | 13 | 14 |
| Completed | 16 | 12 | 16 | 12 | 13 |
| Not completed | 1 | 5 | 1 | 1 | 1 |
The proportion of subjects in the per protocol population with serum 25-hydroxyvitamin D ≥30 ng/mL at End-of-Treatment (EOT; Week 6) in Cohorts 1 and 2 (60/90 and 30 μg groups, respectively) were compared to their corresponding placebo groups.
| percentage of participants | Cohort 1: CTAP101 Capsules 60µg | Cohort 1: CTAP101 Capsules 90µg | Cohort 1: Sugar Capsule | Cohort 2: CTAP101 Capsules 30µg | Cohort 2: Sugar Capsule |
|---|---|---|---|---|---|
| Proportion (%) of Subjects With Serum 25-hydroxyvitamin D ≥30 ng/mL (PP). | 100 | 100 | 0 | 91.7 | 7.1 |
Mean percent change from baseline in plasma intact parathyroid hormone (iPTH) from baseline to End of Treatment (EOT) in the Per Protocol population. Subjects in Cohorts 1 and 2 (dose regimens 60/90 and 30 mcg, respectively) were compared to their respective placebo groups.
| percentage of change from baseline | Cohort 1: CTAP101 Capsules 60µg | Cohort 1: CTAP101 Capsules 90µg | Cohort 1: Sugar Capsule | Cohort 2: CTAP101 Capsules 30µg | Cohort 2: Sugar Capsule |
|---|---|---|---|---|---|
| Mean Percent Change From Baseline in Plasma Intact Parathyroid Hormone (iPTH) to End of Treatment (Per Protocol Population) | -32.77 ± 22.778 | -39.32 ± 16.243 | 20.49 ± 52.871 | -20.86 ± 21.549 | 13.18 ± 30.185 |
Mean absolute change from baseline in serum total 25-hydroxyvitamin D to end of treatment (EOT)
| ng/mL | Cohort 1: CTAP101 Capsules 60µg | Cohort 1: CTAP101 Capsules 90µg | Cohort 1: Sugar Capsule | Cohort 2: CTAP101 Capsules 30µg | Cohort 2: Sugar Capsule |
|---|---|---|---|---|---|
| Change From Baseline in Serum 25-hydroxyvitamin D at Week 6 | 43.25 ± 16.519 | 63.69 ± 17.826 | -0.65 ± 2.502 | 16.22 ± 6.005 | -1.89 ± 4.913 |
Mean percent change from baseline in serum 25-hydroxyvitamin D at End of Treatment (EOT, week 6) in the per protocol population. Subjects in Cohorts 1 and 2 (dose regimens of 60/90 and 30 mcg, respectively) were compared versus their corresponding placebo groups.
| percentage of change from baseline | Cohort 1: CTAP101 Capsules 60µg | Cohort 1: CTAP101 Capsules 90µg | Cohort 1: Sugar Capsule | Cohort 2: CTAP101 Capsules 30µg | Cohort 2: Sugar Capsule |
|---|---|---|---|---|---|
| Percent Change From Baseline in Serum 25-hydroxyvitamin D at End of Treatment (EOT, Week 6) in the Per Protocol Population | 187.64 ± 74.251 | 313.12 ± 101.592 | -2.67 ± 13.069 | 90.90 ± 62.189 | -7.22 ± 20.599 |
Proportion of subjects with at least 30% reduction in plasma intact parathyroid hormone (iPTH) and/or mean iPTH reduction to 70 pg/mL or less at End of Treatment (EOT)
| participants | Cohort 1: CTAP101 Capsules 60µg | Cohort 1: CTAP101 Capsules 90µg | Cohort 1: Sugar Capsule | Cohort 2: CTAP101 Capsules 30µg | Cohort 2: Sugar Capsule |
|---|---|---|---|---|---|
| Proportion of Subjects With Reduction of Intact Parathyroid Hormone (iPTH) of at Least 30% at Week 6 | 11 | 9 | 2 | 5 | 0 |
Proportion of subjects with at least 20% reduction in plasma intact parathyroid hormone (iPTH) and/or mean iPTH reduction to 70 pg/mL or less at End of Treatment (EOT)
| participants | Cohort 1: CTAP101 Capsules 60µg | Cohort 1: CTAP101 Capsules 90µg | Cohort 1: Sugar Capsule | Cohort 2: CTAP101 Capsules 30µg | Cohort 2: Sugar Capsule |
|---|---|---|---|---|---|
| Proportion of Subjects With Reduction of Intact Parathyroid Hormone (iPTH) of at Least 20% at Week 6 | 12 | 13 | 2 | 5 | 1 |
Collected over 12 weeks (6 week treatment period, followed by 6 week follow-up period). Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Cohorts 1,2: Sugar Capsule | — | 1/31 (3.2%) | 22/31 (71%) |
| Cohort 2: CTAP101 Capsules 30µg | — | 1/13 (7.7%) | 8/13 (61.5%) |
| Cohort 1: CTAP101 Capsules 60µg | — | 1/17 (5.9%) | 12/17 (70.6%) |
| Cohort 1: CTAP101 Capsules 90µg | — | 1/16 (6.3%) | 10/16 (62.5%) |
| Event | Cohorts 1,2: Sugar Capsule | Cohort 2: CTAP101 Capsules 30µg | Cohort 1: CTAP101 Capsules 60µg | Cohort 1: CTAP101 Capsules 90µg |
|---|---|---|---|---|
| Cardiac failure congestiveCardiac disorders | 0/31 | 1/13 | 0/17 | 1/16 |
| Renal failure acuteRenal and urinary disorders | 0/31 | 1/13 | 0/17 | 0/16 |
| AngioplastySurgical and medical procedures | 0/31 | 1/13 | 0/17 | 0/16 |
| Acute prerenal failureRenal and urinary disorders | 0/31 | 0/13 | 0/17 | 1/16 |
| Femoral neck fractureInjury, poisoning and procedural complications | 0/31 | 0/13 | 0/17 | 1/16 |
| HypoglycaemiaEndocrine disorders | 0/31 | 0/13 | 1/17 | 0/16 |
| HeadacheNervous system disorders | 1/31 | 0/13 | 0/17 | 0/16 |
| Event | Cohorts 1,2: Sugar Capsule | Cohort 2: CTAP101 Capsules 30µg | Cohort 1: CTAP101 Capsules 60µg | Cohort 1: CTAP101 Capsules 90µg |
|---|---|---|---|---|
| Abdominal discomfortGastrointestinal disorders | 1/31 | 2/13 | 1/17 | 0/16 |
| HyperphosphatemiaMetabolism and nutrition disorders | 0/31 | 2/13 | 1/17 | 1/16 |
| Oedema peripheralGeneral disorders | 3/31 | 0/13 | 0/17 | 2/16 |
| ContusionInjury, poisoning and procedural complications | 3/31 | 0/13 | 0/17 | 2/16 |
| ArthralgiaMusculoskeletal and connective tissue disorders | 0/31 | 0/13 | 1/17 | 2/16 |
| HeadacheNervous system disorders | 2/31 | 0/13 | 1/17 | 2/16 |
| GoutMetabolism and nutrition disorders | 2/31 | 0/13 | 1/17 | 2/16 |
| ConstipationGastrointestinal disorders | 1/31 | 0/13 | 2/17 | 0/16 |
| Coronary artery diseaseCardiac disorders | 0/31 | 1/13 | 0/17 | 0/16 |
| PalpitationsCardiac disorders | 0/31 | 1/13 | 0/17 | 0/16 |
Intent to treat population (excludes a single subject randomized to the 90 µg treatment arm who was lost to follow-up prior to receiving study drug)
| Age, Continuous(years) | Cohort 1: CTAP101 Capsules 60µg | Cohort 1: CTAP101 Capsules 90µg | Cohort 1: Sugar Capsule | Cohort 2: CTAP101 Capsules 30µg | Cohort 2: Sugar Capsule | Total |
|---|---|---|---|---|---|---|
| Mean | 64.7 ± 9.20 | 64.6 ± 11.41 | 61.9 ± 17.79 | 58.2 ± 16.14 | 63.9 ± 11.47 | 63.0 ± 13.39 |
| Sex: Female, Male(Participants) | Cohort 1: CTAP101 Capsules 60µg | Cohort 1: CTAP101 Capsules 90µg | Cohort 1: Sugar Capsule | Cohort 2: CTAP101 Capsules 30µg | Cohort 2: Sugar Capsule | Total |
|---|---|---|---|---|---|---|
| Female | 7 | 9 | 13 | 7 | 7 | 43 |
| Male | 10 | 7 | 4 | 6 | 7 | 34 |
Plan to share: No
No publications or documents are linked to this record.
The record gives a start of Oct 2010, a primary completion of Nov 2011 and a completion of Nov 2011. It does not say whether these dates are actual or estimated.
Results were first posted in Aug 2016, 4 years 9 months after primary completion. A results delay was requested in Sep 2014.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Sep 2014. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Renal Insufficiency, Chronic →